

2019 #21

June 21, 2019

INSIDE:

Zero Risk Remains
Elusive—HIV
Transmission Despite
NAT in France3

Update: Advocacy Efforts
on 14-day Rule for
Advanced Laboratory
Tests4

ABC Spotlight Reporting
Update.....4

2019 Summer Summit &
MD Workshop
Registration Opens.....5

Member Feedback Sought
on AABB Proposed 32nd
Edition of Standards.....5

BRIEFLY NOTED.....6

GLOBAL NEWS6

MEMBER NEWS.....7

COMPANY NEWS8

Upcoming ABC Webinars
– Don't Miss Out!.....8

ABC 2019 Meetings &
Workshops9

CALENDAR.....9

POSITIONS.....10

ABC Names New Senior Director of Federal Government Affairs

Diane Calmus, JD joined America's Blood Centers as the senior director of Federal Government Affairs this week. In her new role, Ms. Calmus will be responsible for developing the organization's public policy priorities that impact member blood centers, and leading advocacy efforts with federal legislators, regulators, and strategic partners.



Previously, Ms. Calmus worked at the National Rural Health Association on a variety of health care issues impacting rural Americans achieving substantial legislative and regulatory victories positively impacting access to care in rural America. She previously served as a legislative assistant to Rep. Kevin Brady (R-Texas) while he was the chair of the health subcommittee for the House Ways and Means Committee. In that role, she focused on Medicare policy in addition to a broad array of health care issues. Ms. Calmus has also worked as a health policy fellow at the Heritage Foundation.

She earned a JD from Michigan State University College of Law and bachelor's degrees in mechanical engineering from Lake Superior State University and psychology from Central Michigan University. Ms. Calmus can be reached at dcalmus@americasblood.org or by phone at (202) 654-2988. ♦

CDC Examines Sepsis Attributed to Bacterial Contaminated Platelets

The Centers for Disease Control and Prevention (CDC) *Morbidity and Mortality Weekly Report* (MMWR) for the week of June 14th detailed that four individuals experienced sepsis following transfusion of bacterially contaminated (*Acinetobacter calcoaceticus-baumannii* complex (ACBC) and *Staphylococcus saprophyticus* platelets) in the report entitled "[Sepsis Attributed to Bacterial Contamination of Platelets Associated with a Potential Common Source — Multiple States, 2018.](#)" The incidents occurred in three states and resulted in one death.

(continued on page 2)



Sepsis Cases in Contaminated Platelets (continued from page 1)

Blood centers and labs have implemented mitigation strategies to prevent transfusion of contaminated platelets, as platelets stored at room temperature can facilitate the growth of bacteria. According to the report, the contaminated units were collected in platelet additive solution via machines and collection sets from the same manufacturer with two originating from the same lot. One unit did undergo pathogen-inactivation, while two units screened by rapid bacterial detection testing were negative with a negative primary culture as well. It states that “[c]linicians should monitor for sepsis after platelet transfusions even after implementation of bacterial contamination mitigation strategies. Recognizing adverse transfusion reactions and reporting to the platelet supplier and hemovigilance systems is crucial for public health practitioners to detect and prevent sepsis associated with contaminated platelets.”

CDC traced three of the contaminated units attributed to septic transfusion reactions back to different donors that did not have any known epidemiologic links to each other and demonstrated no signs of bacteremia or illness. The donors have been indefinitely deferred. The agency acknowledges that platelet transfusion is more likely to cause sepsis than transfusion of other blood products. The authors conclude, “[w]hole genome sequencing analysis indicated an unidentified potential common source of bacterial contamination among the four cases of septic transfusion reactions reported here. Investigation into the contamination source continues... Because the risk for platelet transfusion-associated sepsis has persisted despite implementation of primary cultures, additional bacterial mitigation strategies have been implemented, including pathogen-inactivation technology, rapid bacterial detection devices, and alternative culture strategies. This report underscores the possibility that sepsis resulting from bacterial contamination of platelets can occur even with application of bacterial contamination mitigation strategies. The consequences of septic transfusion reactions are often severe morbidity or mortality. In the cluster reported here, one of four patients died, and three recovered only after receiving intensive care. Even with implementation of bacterial contamination mitigation strategies, clinicians should continue to monitor recipients for sepsis after platelet transfusions and immediately report adverse reactions to the platelet supplier and hemovigilance systems.”

(Source: CDC *Morbidity and Mortality Weekly Report* (MMWR) [Sepsis Attributed to Bacterial Contamination of Platelets Associated with a Potential Common Source — Multiple States, 2018](#), 6/13/19) ♦

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2019 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

lmaundy@americasblood.org

America's Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



Zero Risk Remains Elusive—HIV Transmission Despite NAT in France

Nucleic acid testing (NAT) has been implemented to detect early seronegative infections and has reduced the window period for human immunodeficiency virus (HIV) NAT to 5 to 9 days. The risk of missing HIV-infected donations can happen from inadequacy between the primers and probes used in NAT assays and the sequence of viruses found in blood donors, or from blood donations during the very early phase of infection before NAT becomes positive. France began minipool NAT for HIV in 2001 followed by individual donor testing (IDT) NAT in 2010. This was the first reported case in France of transfusion of HIV-infected blood donated during the HIV pre-ramp up phase that tested IDT NAT negative. France screens blood donations for HIV antibodies and HIV RNA (Procleix Ultrio, Grifols; limit of detection, 23 copies/mL). If a repeat donor tests positive for HIV, a repository sample from the previous donation is tested with the Cobas TaqMan HIV-1 test (CTM, Roche; limit of detection, 17 copies/mL).

In August 2017, a 57-year-old male donor tested positive for HIV antibodies and RNA (plasma viral load, 11,599 copies/mL). He donated five times over a two-year period. The previous donation tested negative with Ultrio in March 2017 but was positive when an archived sample was tested with CTM demonstrating a plasma viral load below the level of detection (34 copies/mL). The sequence of the repository sampled showed a 99.8 percent similarity with that found in a sample collected 12 days after the positive donation. It was consistent with HIV-1/M subtype B (67 percent of strains found in French blood donors). The donor provided no risk factors when interviewed and his partner tested negative for HIV.

Three blood products had been prepared: a Red Blood Cell (RBC), a buffy coat contributing to a whole blood pooled platelet concentrate (PC) in additive solution, and a fresh frozen plasma unit (FFP). The RBC unit had been transfused to a 23-year-old recipient of an allogenic bone marrow transplant who died of graft-vs- host disease six days after transfusion. The detection of HIV RNA performed on a plasma sample collected five days after transfusion was negative. The platelet pool had undergone pathogen reduction and had been transfused to a 62-year-old woman with acute myeloblastic leukemia. HIV serology performed on the patient six months after the transfusion was negative. Finally, the FFP had entered a manufacturing plasma pool for fractionation. No withdrawal was deemed necessary given the very low HIV viral titer in the blood donation and the various pathogen reduction processes. Therefore, HIV transmission was not excluded in the recipient of RBCs due to premature death.

The authors concluded that this case demonstrated that the risk of contaminated donations due to the early HIV infection phase going undetected by highly sensitive NAT is a real concern but a rare event. In France, the residual risk of HIV transmission is estimated at 1 in 5.9 million donations or one case every two years. The article emphasized that hemovigilance data may not represent true residual risk when considering underreporting (e.g., no systematic testing for seroconversion and premature death of recipients) and the fact that contamination through infected blood products does not occur systematically, as shown by the differential transmission of HIV when several blood products were prepared from the same infected donation. This case also highlighted the additional value of repository samples as the authors stress the continued importance of donor education and predonation selection.

Citation: Cappy, P., Barlet, V., Lucas, Q., *et al.* Transfusion of HIV-infected blood products despite highly sensitive nucleic acid testing. *Transfusion* 2019. doi:[10.1111/trf.15203](https://doi.org/10.1111/trf.15203).

Contributed by Richard Gammon, MD, Medical Director at OneBlood ♦

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

Update: Advocacy Efforts on 14-day Rule for Advanced Laboratory Tests

America's Blood Centers (ABC), together with AABB and American Red Cross, continue to advocate for blood centers to be exempt from a Medicare outpatient payment rule published in December 2017 that requires testing laboratories bill Medicare directly for certain Advanced Diagnostic Laboratory Tests (ADLTs) and molecular pathology tests performed on patient samples. We have asked for an exemption or flexibility in the application of the new rule for tests not used for diagnostic purposes. Thank you to all that have supported this effort over the past several months by sharing data and experience.

The Center for Medicare and Medicaid Services (CMS) has recognized the complexity of the rule and has exercised enforcement discretion until July 1, 2019. While CMS has recognized and been receptive to the concerns raised by the blood industry, they have not yet granted an exemption to this new policy or indicated what, if anything, will be done for ADLTs involving blood recipient testing for the purposes of identifying appropriate blood products for transfusion.

Without additional clarity, ABC recommends that member blood centers performing ADLTs and molecular pathology tests on patient samples contact your hospital customers regarding affected tests after July 1, 2019. A template sample notice is available to ABC members for customization in MCN [19-045](#). Please contact [Ruth Sylvester](#) with any questions.

ABC Stoplight Reporting Update

America's Blood Centers (ABC) has transitioned the Stoplight blood supply reporting system to a newer version. Going forward, ABC member blood centers will receive a single inventory request each weekday. During the transition, there may appear to be some short-term fluctuations in the stoplight data that will settle out over time. This is due to differences in how the two systems perform calculations.

It is important that the report be completed daily. This report is used by ABC and reported to AABB for aggregation with American Red Cross data in a report to the U.S. Department of Health and Human Services (HHS) on behalf of the AABB Disaster Task Force. It is the one conduit to keep HHS apprised of the blood inventory status. The national inventory has been tracking lower than normal going into the summer which can potentially have significant implications during the typical summer lull in donations. We urge all members to report their daily inventories so that we have an accurate snapshot.

Thank you for continued support of this important task. Please direct questions or comments to [Ruth Sylvester](#).

(Source: MCN [19-044](#))

(continued on page 5)



INSIDE ABC (continued from page 4)

2019 Summer Summit & MD Workshop Registration Opens

[Registration](#) has launched for the 2019 America's Blood Centers Summer Summit and Medical Directors Workshop in Denver, Colo. July 30th – August 1st at the [Grand Hyatt Denver](#) (reserve rooms by [July 5th](#)). Don't miss an exclusive opportunity to take part in this year's newly designed meeting format that brings together thought leaders throughout the blood community to focus on the future of blood centers and the larger transfusion community. The theme of the Summer Summit is "Defining and Promoting Innovation in the Blood Sector." It will feature leaders from both within and outside the industry, case studies from your blood center peers, and engaging roundtable discussions to promote peer-to-peer collaboration in discussing the latest trends and issues impacting community blood centers. The meeting will also include the Medical Directors Workshop, the Summit Reception, and the Women-Inspiring-Leading-Learning High Tea Luncheon sponsored by Terumo BCT. Member, government, hospital non-member, public, and emeritus registration rates are available [here](#). Contact [Leslie Maundy](#) for available sponsorship opportunities. Click [here](#) for additional meeting information.

Member Feedback Sought on AABB Proposed 32nd Edition of Standards

ABC is seeking the [input](#) of its member blood centers regarding feedback on AABB's proposed [32nd edition of Standards](#) for Blood Banks and Transfusion Services. Blood centers and individual AABB members are encouraged to also submit independently to [AABB](#). The comment period is open until July 9, 2019.

(Source: MCN [19-039](#)) 

AMERICA'S BLOOD CENTERS'
2019 ABC SUMMER SUMMIT
Empower. Influence. Advance.
July 30 - August 1, 2019 | Denver, CO

This year's newly-designed ABC Summer Meeting, now known as the "Summer Summit," will convene thought leaders from across the industry to focus on the future of blood centers and the transfusion medicine community. This year's theme "Defining and Promoting Innovation in the Blood Sector" will feature leaders from outside the industry, case studies from your peers, and interactive peer roundtable discussions. Please join us for this one-of-a-kind experience to be inspired!

2019 SUMMER SUMMIT INCLUDES:
ABC Board Meeting
Medical Directors Workshop
Members Meeting

Networking Events:
General Reception
Women-Inspiring-Leading-Learning High Tea Luncheon



For registration and hotel information, visit
http://bit.ly/2019_summer_summit.

For sponsorship opportunities, please contact Leslie Maundy at лмаundy@americasblood.org.



America's Blood Centers
It's About *Life*.



BRIEFLY NOTED

Ambrosia, a company at the center of the controversial plasma infusions from young donors that allegedly helped with health and aging, has resumed operations in two cities (San Francisco, Calif. and Tampa, Fla.) according to a *Business Insider* [report](#). The company's founder Jesse Karmazin, a Stanford Medical School graduate, said the company is "pursuing an application [with the U.S. Food and Drug Administration (FDA)] to continue our work." Customers can receive infusions of "young blood" for \$8,000 (1 liter) or \$12,000 (2 liters). Earlier this year, the FDA [warned](#) the public about the claims of establishments that offer plasma infusions from young human donors to treat aging and ailments such as dementia and Parkinson's disease. Several establishments had opened around the U.S. marketing the supposed benefits of young plasma infusions, which concerned the FDA. In the February 19th joint [statement](#) released from former FDA Commissioner Scott Gottlieb, MD and director of FDA's Center for Biologics Evaluation and Research (CBER) Peter Marks, MD, PhD, the FDA stated "[t]here is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product...Our concerns regarding treatments using plasma from young donors are heightened by the fact that there is no compelling clinical evidence on its efficacy, nor is there information on appropriate dosing for treatment of the conditions for which these products are being advertised. Plasma is not FDA-recognized or approved to treat conditions such as normal aging or memory loss, or other diseases like Alzheimer's or Parkinson's disease. Moreover, reports we're seeing indicate that the dosing of these infusions can involve administration of large volumes of plasma that can be associated with significant risks including infectious, allergic, respiratory and cardiovascular risks, among others."

(Sources: *Business Insider*, [A controversial startup that charges \\$8,000 to fill your veins with young blood and halted operations after an FDA warning now says it's back up and running](#), 6/17/19; FDA [Advisory](#), 2/19/19; Scott Gottlieb, MD & Peter Marks, MD, PhD Joint [Statement](#), 2/19/19) ♠

GLOBAL NEWS

The *BBC News* [published](#) a story this week on the current 3-month blood donor deferral policy for men who have sex with other men (MSM) in England, Scotland, and Wales. The article examines whether the policy is discriminatory and suggests that some MSM are not abiding by the policy based on interviews with individuals who admit to disregarding the deferral period. "It's not nice that you're almost discriminated against and you know that you are doing something that you shouldn't be doing," stated a donor identified as Ryan in the story who says he has been donating blood for close to 10 years in spite of the deferral period, which was reduced from 12 months in 2017. "How many heterosexual people have sex without contraceptive devices or condoms or anything? How much risk are they taking? I don't think that who I choose to have sexual relations with, or fall in love with, should have any bearing on giving blood. But at the same time, morally, you are helping somebody else by giving blood." Another donor identified by name David acknowledges donating outside of the deferral period as well as being a sexually active MSM that takes pre-exposure prophylaxis (PrEP) medications daily. "It galls me every time I hear an advert on the radio asking for people to give blood, when there's a huge section of society that is just denied that for no good reason. I grew up in a family who gave blood regularly and instilled in me that that was the right thing to do. I did it before I started having sex with men - and I carried on doing it afterwards because, for me, that was the right thing to do...Certainly I don't think the people whose lives I've potentially saved would complain." The Advisory Committee on Safety of Blood, Tissues and Organs that makes recommendations for health departments in the United Kingdom (UK) has guidelines in place to prevent individuals that have used PrEP in the previous three months from donating blood due to the impact of PrEP-use on HIV test results. "The safety of the seriously ill people who receive blood is our number one priority," said Su Brailsford a consultant in health protection at NHS Blood and Transplant (NHSBT) to *BBC News*. "Blood donation exists for patients, not for blood donors. Anyone can acquire a blood-borne

(continued on page 7)

GLOBAL NEWS (continued from page 6)

infection or a sexually transmitted disease, but some people have an increased risk of exposure. At a population level, men who have sex with men have a higher risk. Using protection like condoms or PrEP can reduce this risk but may not eliminate it. We have to consider not only the donor but also the potential risks of their partner. All donors have to complete the donor health check when they come to donate - so it's not just men who have sex with men who we ask about what sort of sex they've been having."

(Source: *BBC News*, [The gay men breaking blood donation rules](#), 6/18/19)

NHSBT has seen a [decline](#) in the number of male donors over the previous five years reports *The Telegraph*. "Men are more likely to be able to donate, and able to help more patients with each donation, so we need a new generation of young male donors to ensure our donor base is strong enough to keep supplying lifesaving blood to hospitals," said NHSBT Director of Blood Donation Mike Stredder in the article. The UK's national blood collection agency revealed that close to a 25 percent decline exists today in comparison to the total number of male donors in 2013-14 (466,346 vs. 350,425), which is being attributed to several reasons as NHSBT analyzes the disturbing trend. "Factors affecting male donor recruitment are thought to include the popularity of social media appeals, which are more popular with women," said the NHSBT to *The Telegraph*. "Men are more likely to view their first donation as a personal achievement, whereas women are more likely to be motivated by altruism." The organization also speculated that the behavior of male donors is influenced more by knowing who the recipient of their blood donation is.

(Source: *The Telegraph*, [Blood donations from men plummet as NHS says they are less motivated by altruism than women](#), 6/10/19)

Bluebird Bio has priced its gene therapy treatment for transfusion-dependent beta thalassemia patients (Zynteglo™) at €1.6 million. According to a [report](#) in the *Wall Street Journal*, customers can make payments over a five year period and Bluebird Bio would only request full payment in cases with successful treatment outcomes. "We only get paid if our therapy works, with annual payments capped at five years, versus continued lifelong treatment and cost," said Bluebird CEO Nick Leschly to the publication. It had previously been speculated that the gene therapy treatment would [sell](#) for closer to \$800K per patient. The European Commission (EC) recently approved the sale of Zynteglo™ in member states, as Bluebird Bio is expected to seek U.S. clearance from the U.S. Food and Drug Administration later this year. The company held a live webcast earlier this month [announcing](#) the EC approval.

(Sources: *Wall Street Journal*, [New gene therapy priced at \\$1.8 million in Europe](#), 6/14/19; *Reuters*, Bluebird Bio News [Release](#), 6/6/19; [EMA panel recommends approval of Bluebird Bio's first gene therapy](#); 3/29/19)

MEMBER NEWS

The Blood Connection, Inc held a four-day blood drive last month to honor veterans and fallen soldiers. It partnered with the Wounded Warrior Project by donating \$10 to the Blood Centers of America Special Forces Wounded Warrior Fund for each donor. More than 700 registered donors participated as The Blood Connection contributed more than \$7,000 to the fund. Individuals also dedicated pinwheels to loved ones, which were displayed at the centers.



(Source: The Blood Connection [Announcement](#), 6/14/19)

(continued on page 8)



MEMBER NEWS (continued from page 7)



San Diego Blood Bank announced the results of their 3rd annual Padres Summer Blood Drive. More than 465 pints were collected, an increase of more than 100 pints from last year. “We are so grateful to the Padres, our sponsors and our community for helping to bring our blood supply up to a sufficient level as we head into the summer,” said San Diego Blood Bank CEO David Wellis, PhD in a news release. “The summer months are some of the toughest for blood banks across the country. This drive is literally a lifesaver for local hospital patients.” The drive took place at Petco Park, home of Major League Baseball’s San Diego Padres franchise, as donors received a voucher for two tickets to a Padres game and VIP access to an autograph booth.

(Source: San Diego Blood Bank News [Release](#), 6/18/19) ♦

COMPANY NEWS

Grifols recently announced a partnership with Ethicon to provide plasma-protein-based products such as VISTASEAL™, a fibrin sealant that uses airless spray device technology, to combat surgical bleeds. “Grifols is committed to applying its plasma leadership to its collaboration with Ethicon, whose strengths in device technology and market success in reaching millions of patients worldwide enable us to make important advances in biosurgery and the control of surgical bleeding,” said Eduardo Herrero, president Grifols Bioscience Industrial Group in a news [release](#). VISTASEAL™ will be named VERASEAL™ in non-U.S. markets and should be available later this year.

(Source: Grifols News [Release](#), 6/19/19)

Blood Centers of America (BCA) has [partnered](#) with the esports professional organization Team Liquid to target blood donors within the young adult demographic. “We’re proud to partner with Blood Centers of America and its members on this live-saving initiative,” said Team Liquid Co-CEO and Owner Steve Arhancet in a news [release](#). “Our fans are such a supportive, tight-knit community, and now we’re calling on them to help us accomplish something bigger than what we could achieve in any competition. Collectively, we have the opportunity to make a measurable impact on communities as well as save lives.” Through the partnership, made possible by a grant from The Commonwealth Transfusion Foundation. “What we see is that over 45 percent of blood donations come from donors that are over 50, and the average age of donors is increasing each year,” said BCA President and CEO Bill Block in the news release. “We need to engage younger generations in order to maintain an available blood supply... This is a unique opportunity for us to reach a crucial demographic of eligible blood donors in the U.S.” Team Liquid is a leading international multigame esports organization whose teams compete in various gaming competitions.



(Source: BCA News [Release](#), 6/6/19) ♦

Upcoming ABC Webinars – Don’t Miss Out!

- **QA Education Webinar – Change Management** – July 16th. Additional details forthcoming!
- **SMT Journal Club Webinar** – August 19. Additional details forthcoming!



ABC 2019 Meetings & Workshops				
Meeting/Workshop	Dates	Location	Hotel/Hotel Rate	Registration Dates & Fees
Medical Directors Workshop	July 30 (precedes Summer Mtg)	Denver, CO	Grand Hyatt, \$239/night	Register by July 5!
Summer Summit	July 31-August 1	Denver, CO	Grand Hyatt, \$239/night	Register by July 5!

Notes:
For the most up-to-date information on all events, members of ABC may check the [calendar](#) on ABC's Member Site. Non-members may attend all events; information will be updated on ABC's [Public Site](#).



CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published in the last issue of each month) are welcome. Send information to Leslie Maundy by e-mail (lmaundy@americasblood.org) or by fax to (202) 393-1282. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2019

July 30-Aug. 1. **2019 ABC Summer Summit & Medical Directors Workshop, Denver, Colo.** More details available [here](#).

Sept. 23-25. **The MedTech Conference, powered by AdvaMed, Boston, Mass.** More details available [here](#).

2020

Mar. 9-11. **2020 ABC Annual Meeting, Washington, DC.** More details coming soon.

May 13-14. **IPFA/PEI 27th International Workshop on "Surveillance and Screening of Blood-Borne Pathogens, Porto, Portugal.** More details available [here](#).

May 19-21. **2020 ADRP Conference, Phoenix, Ariz.** More details coming soon. 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, contact Leslie Maundy at the ABC office. Phone: (202) 654-2917; fax: (202) 899-2621; e-mail: lmaundy@americasblood.org.

POSITIONS

Senior Director of Donor Recruitment and Marketing. The Community Blood Center of the Ozarks (CBCO) is seeking a Senior Director who will be responsible for the effective and efficient management of Donor Recruitment and Marketing departments in our area. This position coordinates recruitment and collection activities to produce balanced collections. Creates a positive working relationship with all customers. Ensures that a high standard of customer service is maintained at all times. Production planning through coordination with other departments is essential. Qualified candidates with a Bachelor of Science/Arts degree in communications, marketing, business, or closely related field are preferred. Managerial, marketing/sales, analytics, blood recruitment, and communication experience preferred. CBCO offers a comprehensive benefit package and pay commensurate with experience. Qualified candidates should send a cover letter and resume to Stacey Connell, Senior Director of Human Resources at connells@cbco.org. CBCO is an Equal Opportunity Employer and a Tobacco Free Workplace.

Medical Technologist I. Essential Functions: Prepares laboratory reagents and chemicals; performs laboratory quality control tasks; performs equipment maintenance and quality control; performs tasks associated with red cell and platelet antibody detection and identification; antigen typing of red cells and platelets; antibody ID, ABO/Rh, DAT testing; platelet antibody testing; problem solving; identifies, tests, and provides specialty typed red cell components based on client requests; provides consultation and reference services to clients; performs patient antibody identification/problem solving; provides communication with hospitals transfusion service staff; reports and bills for patient test results; and provides excellent customer service and communication to internal and external clients. Requirements: B.S. Degree in Clinical Laboratory Science or other applicable science required. MLS (ASCP), MT (ASCP) or equivalent certification required. One to three years blood bank laboratory experience preferred. Skills and Knowledge: Must be able to effectively communicate using verbal and written skills; confidently read, write, speak, and understand English; knowledge of Immunohematology/Transfusion Medicine; attention to detail; stress management skills; ability to solve problems and work independently within the scope of the tasks; ability to work with others in a team environment and individually; and excellent organizational and time

management skills. To apply please visit www.savealifenow.org.

Medical Director. If you have a passion to join a team that is providing cutting-edge medical expertise in the areas of blood banking, transfusion medicine, immunohematology reference laboratories, therapeutic apheresis, cellular therapy and research, consider joining OneBlood as a Medical Director. Qualified candidates should possess a minimum of three years' experience and a M.D. or D.O. degree with board certification in Clinical Pathology, Internal Medicine or Hematology and subspecialty board certified in Blood Banking/Transfusion Medicine by a Board Registry recognized by the American Board of Medical Specialties. Appropriate state licenses will be required as needed. Must meet the eligibility requirements to obtain appointments at hospitals served by OneBlood. This position includes the option of free medical coverage with a competitive benefit package, 403(b) retirement plan with company contribution PLUS a company match, company vehicle lease/allowance, paid holidays, and much more. This position will be based out of the Jacksonville, Florida area, with some of the most gorgeous beaches in the nation! If you want to join our life saving mission and team of dedicated employees, visit our *Careers* page at www.oneblood.org to learn more. OneBlood, Inc., a proven leader in blood banking, is an Equal Opportunity Employer/Vet/Disability.

Laboratory Services Manager. LifeSouth Community Blood Centers is currently seeking a skilled individual for a Laboratory Services Manager position in our Immunohematology Reference Laboratory in Gainesville, FL. This position is responsible for overseeing all laboratory testing activities performed in the LifeSouth facility. This includes meeting the needs of customers for accurate, timely and high-quality immunohematology reference laboratory testing and services. This position is also responsible for compliance with established laboratory policy and with applicable governmental regulatory requirements from CLIA, FDA, AABB, HIPAA and state licensing regulations. Bachelor's degree in clinical laboratory, chemical or biological science required. SBB Certification required. Five years of clinical laboratory experience at a licensed, certified or accredited facility required. Previous management experience required. Master's degree may compensate for less experience. Re

(continued on page 11)

POSITIONS (continued from page 10)

location expenses negotiable. Background check and drug test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. VEVRAA Federal Contractor. Follow this link to apply: <https://lifesouth.careerplug.com/jobs/901033/apps/new>.

Medical Director. Provide transfusion medicine (TM) clinical care at Heartland Blood Center (HBC) and its associated hospitals in the scope noted below, as well as effort in leadership of the Immunohematology Reference Laboratory (IRL) as Medical Director at HBC/Versiti. Key components of this position would comprise TM consultation and oversight of blood management at HBC and Versiti partner hospitals, as well as participation in educational initiatives and clinical/applied research within both Versiti blood centers and their affiliated health systems. Primary Responsibilities: Oversees blood donor center collections in the Chicagoland and various areas of Indiana. Provides medical direction, including compliance with local, state, and federal regulations and accreditation agencies, for blood center and transfusion services at Versiti affiliated hospitals in Illinois and Indiana. IRL Medical Director for HBC, providing oversight of IRL laboratory staff technical duties and working with Versiti and HBC laboratory management to provide education and skill advancement. Education and Licenses: M.D. or D.O. Degree. Board certified in pathology (AP/CP or CP only), internal medicine, or pediatrics (with subspecialty boards in hematology). Board certified/board eligible in Blood Banking/Transfusion Medicine (American Board of Pathology—ABP). Current or eligible for medical licenses in Illinois, Wisconsin, Indiana, Michigan and Ohio. Experience/Certifications: Demonstrated experience in both 1) pathology/laboratory medicine or hematology and 2) transfusion medicine. Ability to write lectures and articles using original or innovative techniques or styles; excellent presentation skills with capacity to present to varied audiences. Click [here](#) to view the full job description and to apply.

Operations Manager. Blood Assurance is seeking an Operations Manager to manage our collection efforts in greater Chattanooga, TN and surrounding areas. This position will be responsible for operational oversight of collection services for multiple collection teams in an assigned territory. Supervises staff in coordination with other department leaders and ensures compliance with all Standard Operating Procedures, FDA and AABB regulations. Monitors performance in the areas of productivity, proficiency and customer service. A bachelor's degree with some prior supervisory/ management experience in blood banking is required. Advanced skills in leadership, teamwork, analytics and communications are also required. Blood Assurance offers a competitive base wage with healthcare benefits and a 401K retirement plan. Qualified candidates are encouraged to submit an online employment application for consideration at www.bloodassurance.org. Blood Assurance is an Equal Opportunity Employer and a Tobacco Free Workplace.

